On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime.

Researchers are warning that men who regularly dodge prostate cancer screening appointments are 45% more likely to die from the disease. Prostate cancer is the most common cancer among men and the ...

The MHRA has approved the product for three clinical settings, including identifying how far high-risk prostate cancer has ...

In addition, about 1 in 44 men will die from the disease ... prostate cancer patients and in patients with early-stage prostate cancer who initially respond to androgen-receptor targeted therapies.